News Nipro Corporation

Stocks

8086

JP3673600007

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange 02:30:00 2026-10-29 EDT			5-day change	1st Jan Change
1,351.50 ^JPY	+1.05%		+0.37%	-8.50%

10-01	Nipro Vascular Innovations Americas Completes Enrollment in the Great Pivotal Trial Evaluating the Golazo Peripheral Atherectomy System	CI
09-21	Nipro Corporation(TSE:8086) dropped from FTSE All-World Index	CI

All News

Mentions Relevance

10-01	Nipro Vascular Innovations Americas Completes Enrollment in the Great Pivotal Trial Evaluating the Golazo Peripheral Atherectomy System	CI
09-21	Nipro Corporation(TSE:8086) dropped from FTSE All-World Index	CI
07-30	Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States	CI
07-30	NIPRO : Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States	PU
07-28	Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million.	CI
07-14	Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold	MT
05-12	Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027	CI
05-12	Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027	CI
05-01	Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold	MT
03-25	Nipro : Announcement of Investment by Development Bank of Japan Inc. in a U.S. Subsidiary of NIPRO	PU
03-24	Nipro : Notice Concerning Change in Depreciation Method	PU
03-17	Nipro : Announcement of Spryte Medical, a US Affiliate of NIPRO, First Participants Enrolled in the “INSYTE” US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment	PU
03-11	Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend	MT
03-11	Nipro : Notice Concerning the Establishment of the Record Date for the Year-End Dividend	PU
02-25	Nipro : Announcement of Expansion of Commercial Collaboration Between Gentuity LLC, a US Affiliate of NIPRO, and GE HealthCare	PU
02-25	Nipro : Notice Regarding the Establishment of the Nomination and Compensation Committee	PU
02-08	Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
02-03	Nipro : Announcement of Avantec Vascular, a US Affiliate of NIPRO, Receives FDA 510(k) clearance of DVT-Focused Thrombectomy System	PU
12-24	Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore	CI
12-15	Nipro : Notice of Subsidiary Name Change and Transfer of Sales Organization of Vascular Division	PU
12-07	Nipro : Investment Agreement with the GHIT Fund on the development of a new detection kit for Mpox	PU
11-20	Nipro : Announcement of Spryte Medical, a US Affiliate of NIPRO, Receives FDA IDE Approval to Initiate "INSYTE" US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment	PU
11-10	Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025	CI
25-10-28	Nipro : Notice Concerning Acquisition of Shares of G2/Spryte Holdco, LLC (to Make It a Subsidiary)	PU
25-08-29	NIPRO : Strengthens Americas Presence with Trade Name Change to Nipro Americas Group	PU